34132-35-9

Basic information

• Product Name: 2,4-dimethoxy-3-bromo-6-methyl-benzoic acid methyl ester
• Synonyms: 2,4-dimethoxy-3-bromo-6-methyl-benzoic acid methyl ester
• CAS NO: 34132-35-9
• Molecular Weight: 289.126
• Mol File: 34132-35-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2,4-dimethoxy-3-bromo-6-methyl-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dimethoxy-3-bromo-6-methyl-benzoic acid methyl ester(34132-35-9)
• EPA Substance Registry System: 2,4-dimethoxy-3-bromo-6-methyl-benzoic acid methyl ester(34132-35-9)

Safety Data

• Hazardous Substances Data: 34132-35-9(Hazardous Substances Data)

Upstream product

• 58106-55-1 2,4-dihydroxy-3-bromo-6-methyl-benzoic acid methyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 72935-17-2 2,4-dimethoxy-3-bromo-6-bromomethyl-benzoic acid methyl ester 

Relevant articles and documents

Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1

There still remains a need to develop new anti-HCV agents with distinct mechanism of action (MOA) due to the occurrence of resistance to direct-acting antiviral agents (DAAs). Cajanine, a stilbenic component isolated from Cajanus cajan L., was identified as a potent HCV inhibitor by phenotypic screening in this work (EC50 = 3.17 ± 0.75 μM). The intensive structure optimization provided significant insights into the structure-activity relationships. Furthermore, the MOA study revealed that cajanine inhibited HCV replications via down-regulating a cellular protein chondroitin sulfate N-acetylgalactosaminyltransferase 1. In consistency with this host-targeting mechanism, cajanine showed the similar magnitude of inhibitory activity against both drug-resistant and wild-type HCV and synergistically inhibited HCV replication with approved DAAs. Taken together, our study not only presented cajanine derivatives as a novel class of anti-HCV agents but also discovered a promising anti-HCV target to combat drug resistance.

CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE

Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.